← Back to Search

Ketamine vs Lidocaine for Rib Fractures

Phase 4
Recruiting
Research Sponsored by Brittany Kiracofe
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up will capture retrospectively after patient's medical discharge
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial will compare ketamine and lidocaine infusions to reduce opioid consumption in the first 72 hours for patients with multiple traumatic rib fractures.

Who is the study for?
Adults over 18 with at least three traumatic rib fractures, enrolled within 16 hours of hospital admission. Not for those already on certain pain treatments, with severe brain injury, communication barriers, extreme weight or specific medical conditions like heart failure, liver disease or kidney failure. Pregnant/breastfeeding women and prisoners are excluded.
What is being tested?
The trial is testing ketamine versus lidocaine infusions to manage pain and reduce opioid use in the first 72 hours after multiple traumatic rib fractures. It aims to see which drug works better for pain control without relying heavily on opioids.
What are the potential side effects?
Ketamine may cause changes in blood pressure, abnormal dreams, dizziness or nausea. Lidocaine could lead to numbness around the mouth, tingling sensations, lightheadedness or a drop in blood pressure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-24; 24-48; 48-72 hours post infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-24; 24-48; 48-72 hours post infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Adverse events
Hospital Length of Stay
In-Hospital mortality
+6 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Group I: KetamineActive Control1 Intervention
Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr\* as needed every 4 hours based on pain scores ≥5 and physician order Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission.
Group II: LidocaineActive Control1 Intervention
Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr\* as needed every 4 hours based on pain scores ≥5 and physician order Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission.

Find a Location

Who is running the clinical trial?

Brittany KiracofeLead Sponsor
Brittany HoyteLead Sponsor

Media Library

Ketamine Clinical Trial Eligibility Overview. Trial Name: NCT04781673 — Phase 4
Traumatic Rib Fracture(s) Research Study Groups: Ketamine, Lidocaine
Traumatic Rib Fracture(s) Clinical Trial 2023: Ketamine Highlights & Side Effects. Trial Name: NCT04781673 — Phase 4
Ketamine 2023 Treatment Timeline for Medical Study. Trial Name: NCT04781673 — Phase 4
~9 spots leftby Jul 2025